Passion of the radiobiologist.

Remember the pathologic complete response rate with neoadjuvant SBRT for early-stage non-small cell lung cancer (NSCLC) on the MISSILE-NSCLC trial? 60%—a number some find impressive, others eye-poppingly bad, and this guy a gross underestimation. His commentary points out that measuring path response at 10 weeks via H&E staining completely ignores the much slower mitotic death rates known to occur in NSCLC. | Scarbrough, JAMA Oncol 2019